FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022056018> ?p ?o ?g. }

• W2022056018 endingPage "181" @default.
• W2022056018 startingPage "173" @default.
• W2022056018 abstract "With the introduction of HAART, the HIV-1 has turned from a lethal into a chronic infection in the majority of patients. In homosexual populations, 20% of HIV-1 infected patients suffer from a chronic HBV infection, which may eventually lead to complications of the liver disease because of prolonged survival. Lamivudine is effective in reducing both HIV-1 and HBV viral replication. However, resistance for lamivudine may complicate the course of the HBV disease in HIV-1-infected patients. We, therefore, conducted a retrospective study in HIV-1-HBV co-infected patients on lamivudine therapy.All HIV-1-HBV co-infected patients who were treated with lamivudine for over 6 months in five major referral clinics in The Netherlands with HBV DNA above 2.0 x 10(5) geq ml(-1) at baseline, were evaluated. Retrospectively, the course of HBV DNA in available serum samples was established. If HBV DNA was detectable with the sensitive PCR-assay, YMDD-analyses of the polymerase gene of the hepatitis B virus was executed with the INNO-LiPA-DR-strip.Forty-six patients were evaluated. The median level of HBV DNA at start of lamivudine therapy was 1.31 x 10(9) geq ml(-1) (range 3.5 x 10(5) - 2.0 x 10(10), n=43). Of three patients no baseline sample was available, but since HBV DNA was still above 2.0 x 10(5) geq ml(-1) at week 3, 7 and 11, these patients were included. Median duration of lamivudine therapy was 97 weeks (range 27-263). The percentage of detected mutations was 25 and 52% at 1 and 2 years, respectively. Twenty-two patients ultimately developed a mutation. Both baseline Body Mass Index (BMI) and the decrease in CD4 cell count as a time dependent factor were significantly related to the emergence of mutations. In 10 out of 12 evaluated patients, HBV DNA levels returned to baseline level or even above baseline level after the development of mutant virus. One patient (5%) developed a flare of serum transaminases (ALT>10 x ULN) 24 weeks after first detection of variant virus.There is a linear time-dependent appearance of HBV mutations for lamivudine in our population. In a minority of patients (5%), development of a mutation was followed by a significant elevation of serum transaminases. A decline in CD4 cell count, which may indicate less response to HAART, induces a faster emergence of mutations and close surveillance of HBV co-infected patients on therapy may be indicated due to the prolonged survival of HIV-1 patients." @default.
• W2022056018 created "2016-06-24" @default.
• W2022056018 creator A5004434511 @default.
• W2022056018 creator A5005200745 @default.
• W2022056018 creator A5016878897 @default.
• W2022056018 creator A5027819349 @default.
• W2022056018 creator A5031051209 @default.
• W2022056018 creator A5035631448 @default.
• W2022056018 creator A5055923700 @default.
• W2022056018 creator A5064368582 @default.
• W2022056018 creator A5067277048 @default.
• W2022056018 date "2002-04-01" @default.
• W2022056018 modified "2023-10-10" @default.
• W2022056018 title "Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort" @default.
• W2022056018 cites W1800895924 @default.
• W2022056018 cites W1965747579 @default.
• W2022056018 cites W1974989911 @default.
• W2022056018 cites W1985577568 @default.
• W2022056018 cites W2001985281 @default.
• W2022056018 cites W2009185691 @default.
• W2022056018 cites W2026323517 @default.
• W2022056018 cites W2029301467 @default.
• W2022056018 cites W2032856863 @default.
• W2022056018 cites W2033597506 @default.
• W2022056018 cites W2036762632 @default.
• W2022056018 cites W2045953763 @default.
• W2022056018 cites W2062388675 @default.
• W2022056018 cites W2070341160 @default.
• W2022056018 cites W2085990351 @default.
• W2022056018 cites W2095273553 @default.
• W2022056018 cites W2098800671 @default.
• W2022056018 cites W2099509337 @default.
• W2022056018 cites W2114132376 @default.
• W2022056018 cites W2123785057 @default.
• W2022056018 cites W2125108762 @default.
• W2022056018 cites W2169661908 @default.
• W2022056018 cites W2318289184 @default.
• W2022056018 cites W2323719395 @default.
• W2022056018 cites W2338794667 @default.
• W2022056018 cites W2410199721 @default.
• W2022056018 cites W4246921863 @default.
• W2022056018 cites W4255024741 @default.
• W2022056018 cites W1995387277 @default.
• W2022056018 doi "https://doi.org/10.1016/s1386-6532(01)00245-1" @default.
• W2022056018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11856618" @default.
• W2022056018 hasPublicationYear "2002" @default.
• W2022056018 type Work @default.
• W2022056018 sameAs 2022056018 @default.
• W2022056018 citedByCount "53" @default.
• W2022056018 countsByYear W20220560182012 @default.
• W2022056018 countsByYear W20220560182013 @default.
• W2022056018 countsByYear W20220560182014 @default.
• W2022056018 countsByYear W20220560182015 @default.
• W2022056018 countsByYear W20220560182016 @default.
• W2022056018 countsByYear W20220560182019 @default.
• W2022056018 countsByYear W20220560182020 @default.
• W2022056018 countsByYear W20220560182023 @default.
• W2022056018 crossrefType "journal-article" @default.
• W2022056018 hasAuthorship W2022056018A5004434511 @default.
• W2022056018 hasAuthorship W2022056018A5005200745 @default.
• W2022056018 hasAuthorship W2022056018A5016878897 @default.
• W2022056018 hasAuthorship W2022056018A5027819349 @default.
• W2022056018 hasAuthorship W2022056018A5031051209 @default.
• W2022056018 hasAuthorship W2022056018A5035631448 @default.
• W2022056018 hasAuthorship W2022056018A5055923700 @default.
• W2022056018 hasAuthorship W2022056018A5064368582 @default.
• W2022056018 hasAuthorship W2022056018A5067277048 @default.
• W2022056018 hasConcept C126322002 @default.
• W2022056018 hasConcept C159047783 @default.
• W2022056018 hasConcept C203014093 @default.
• W2022056018 hasConcept C2522874641 @default.
• W2022056018 hasConcept C2777382497 @default.
• W2022056018 hasConcept C2777869810 @default.
• W2022056018 hasConcept C2780593183 @default.
• W2022056018 hasConcept C71924100 @default.
• W2022056018 hasConcept C90924648 @default.
• W2022056018 hasConceptScore W2022056018C126322002 @default.
• W2022056018 hasConceptScore W2022056018C159047783 @default.
• W2022056018 hasConceptScore W2022056018C203014093 @default.
• W2022056018 hasConceptScore W2022056018C2522874641 @default.
• W2022056018 hasConceptScore W2022056018C2777382497 @default.
• W2022056018 hasConceptScore W2022056018C2777869810 @default.
• W2022056018 hasConceptScore W2022056018C2780593183 @default.
• W2022056018 hasConceptScore W2022056018C71924100 @default.
• W2022056018 hasConceptScore W2022056018C90924648 @default.
• W2022056018 hasIssue "3" @default.
• W2022056018 hasLocation W20220560181 @default.
• W2022056018 hasLocation W20220560182 @default.
• W2022056018 hasOpenAccess W2022056018 @default.
• W2022056018 hasPrimaryLocation W20220560181 @default.
• W2022056018 hasRelatedWork W1964792389 @default.
• W2022056018 hasRelatedWork W1993993021 @default.
• W2022056018 hasRelatedWork W2040973434 @default.
• W2022056018 hasRelatedWork W2052260190 @default.
• W2022056018 hasRelatedWork W2094115803 @default.
• W2022056018 hasRelatedWork W2307814414 @default.
• W2022056018 hasRelatedWork W2349537382 @default.
• W2022056018 hasRelatedWork W2359618769 @default.

• next